Orthogonal Strategies: Dual RNAscope ISH-IHC: HLA-DR Antibody (L243) [NB100-77855] - Formalin-fixed paraffin-embedded tissue sections of human metastatic tonsil were probed for HLA-DR mRNA (ACD RNAScope probe, ...read more
Western Blot: HLA-DR Antibody (L243) [NB100-77855] - Analysis of human spleen (A) and human tonsil (B) tissue using HLA-DR antibody at 2 ug/mL.
Immunohistochemistry-Paraffin: HLA-DR Antibody (L243) [NB100-77855] - Staining of HLA-DR in human spleen using DAB with hematoxylin counterstain.
Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the FITC conjugate of NB100-77855. Staining of Human peripheral blood lymphocytes with L243 FITC.
Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Human peripheral blood lymphocytes stained with L243 PE
Flow (Cell Surface): HLA-DR Antibody (L243) [NB100-77855] - Analysis using the Azide Free version of NB100-77855. Staining of HLA-DR expression by 5x10^5 BDCM cells using 0.5 ug of (red) and 0.5 ug of isotype control ...read more
Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the PerCP/Cy5.5 conjugate of NB100-77855. Staining of HLA-DR expression by 5x10^5 human PBMC using 10 uL (0.25 ug) of this antibody. Cell surface ...read more
Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the Alexa Fluor (R) 700 conjugate of NB100-77855. Staining of HLA-DR protein in human PBMCs using HLA-DR antibody [clone L243; conjugated to Alexa ...read more
Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the Biotin conjugate of NB100-77855. Staining of Human peripheral blood lymphocytes with biotinylated L243, followed by Sav-PE.
Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the DyLight 405 conjugate of NB100-77855. Staining of HLA-DR in human PBMCs using anti-HLA-DR antibody. Image from verified customer review.
It is recommended that the reagent be titrated for optimal performance for each application. This antibody is CyTOF ready. Use in blocking/neutralizing reported in scientific literature (PMID: 12874328). Use in functional reported in scientific literature (PMID: 17900279). Use in ELISA reported in scientific literature (PMID: 11070170). Use in In vitro reported in scientific literature (PMID: 19620786). Use in Immunocytochemistry/immunofluorescence reported in scientific literature (PMID: 7835916). Use in electron microscopy reported in scientific literature (PMID: 21660937)
28 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read 1 Review rated 5 using NB100-77855 in the following applications:
Predicted cross-reactivity with Chimpanzee, Baboon, Cynomolgus, Rhesus, Marmoset, Tamarin, Squirrel Monkey and Canine.
Packaging, Storage & Formulations
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
0.05% Sodium Azide
Protein A purified
Alternate Names for HLA-DR Antibody (L243)
histocompatibility antigen HLA-DR alpha
HLA class II histocompatibility antigen, DR alpha chain
major histocompatibility complex, class II, DR alpha
MHC cell surface glycoprotein
MHC class II antigen DRA
MHC Class II DR
The L243 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD alpha (heavy) chain and a 27 kD beta (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. L243 has been reported to block mixed lymphocyte reactions.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The whole blood cells were lysed to get rid of the RBC. The washed cell were then incubated with the Antibody. They were washed and then incubated with a conjugated secondary. Allowed to sit for 20mins and then washed again and read on the BD Fortessa.
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
FAQs for HLA-DR Antibody (NB100-77855). (Showing 1 - 1 of 1 FAQs).
We have an inquiry of your product Cat. ID # NB100-2735, NB600-1185, NB100-77758, NB100-78016, NB100-77855. We are interested in this product and would like to make sure that there is no any other protein added in the buffer. I saw the storage buffer in datasheet doesn't has any other protein but still would like to confirm with you again. Would you please help us to check and provide the purification method and buffer of the antibody?
Thank you for your inquiry. Catalog numbers NB100-77758, NB100-78016 and NB100-77855 are in a buffer containing PBS and sodium azide. NB600-1185 is in a buffer containing PBS, 150mM NaCl and sodium azide. NB100-2735 is whole tissue culture supernatant and may therefore contain other proteins.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.